TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

The purpose of this study is to: - Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) events - Evaluate the efficacy of nucresiran compared to placebo on additional assessments of CV events and/or death - Evaluate the efficacy of nucresiran compared to placebo on patient-reported health status and health-related quality of life.

For more information:NCT07052903